SPECT/CT predicts treatment response in Pluvicto patients
AuntMinnie
NOVEMBER 1, 2024
SPECT/CT scans taken just four hours after patients begin lutetium-177 (Lu-177) prostate-specific membrane antigen-617 (PSMA-617) treatment can help assess treatment responses, according to researchers in Australia. A team at St Vincent’s Hospital in Sydney noted that the approach may serve as an alternative to scans performed 24 hours after initial treatment and allow imaging and treatment on the same day, which would be more convenient.
Let's personalize your content